on Quantum Biopharma Ltd.
Quantum BioPharma Concludes Second Tranche of Offering
Quantum BioPharma Ltd. (NASDAQ:QNTM) announced the completion of its second tranche, issuing 500 Debenture Units at $500,000. The funds will support business model development and general working capital. This issuance follows the announcement made on December 5, 2024.
The securities related to this tranche are under a statutory hold period of four months and one day. Expressed in Canadian dollars, the offering has not been registered under the U.S. Securities Act, restricting its sale in the United States without registration or an exemption.
Quantum BioPharma focuses on biopharmaceutical advancements, particularly for neurological and metabolic disorders, and holds strategic investments through its subsidiary, FSD Strategic Investments Inc.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Quantum Biopharma Ltd. news